recall-plan

name	recall-plan
language	en
description	Drafts FDA product recall plans compliant with 21 CFR Part 7, covering Recall Committee governance, health hazard evaluation, recall classification, notification protocols, effectiveness checks, product disposition, and termination procedures. Use when developing recall SOPs, updating recall procedures, drafting recall readiness plans, or preparing FDA-regulated product recall documentation.

Recall Plan and Procedure

Drafts the company's official FDA-compliant recall protocol under 21 CFR Part 7 and the FD&C Act.

Prerequisites

Gather before drafting:

• Company profile — product categories, distribution channels, manufacturing sites
• Existing QMS documents — quality manual, CAPA procedures, complaint handling SOPs
• Regulatory filings — NDC numbers, device ID codes, 510(k)/PMA references
• Organizational chart — key personnel in QA, Regulatory, Legal, Operations, Communications, Executive
• Distribution records — channel structure, geographic scope, sub-distribution
• Prior recall history (if any) — FDA correspondence, lessons learned

Quick Start

1. Collect prerequisites and confirm product scope
2. Draft each section below in order
3. Flag evolving guidance with [VERIFY CURRENT GUIDANCE]
4. Route draft through Legal and Regulatory review

Core Sections

1. Purpose and Scope

State commitment to consumer safety, applicability to all FDA-regulated products, and governing authority (21 CFR Part 7, FD&C Act).

2. Recall Committee

Define these roles with named personnel:

Role	Typical Position	Key Duties
Chair	VP Quality+	Final recall decisions, FDA liaison oversight
Regulatory Lead	Head of RA	FDA notifications, classification coordination
Legal Counsel	GC / Outside Counsel	Risk assessment, notification review, litigation hold
Operations Lead	Head of Mfg/Supply Chain	Retrieval logistics, inventory quarantine
Communications Lead	Head of Corp Comms	Press releases, social media, consumer contact
Quality Lead	QA Director	HHE, effectiveness checks, CAPA

Convening: Within 4 hours (business) / 12 hours (after-hours). Maintain emergency contact tree with 2 backups per role and documented alternates.

Decisions: Consensus preferred; Chair has unilateral emergency authority. Document rationale, attendees, and dissenting views.

3. Health Hazard Evaluation (HHE)

Assess these factors in a formal report with supporting data:

• Nature of defect (contamination, mislabeling, malfunction)
• Adverse outcome likelihood (scientific/medical evidence)
• Vulnerable populations (pediatric, immunocompromised, elderly)
• Severity x probability of harm
• Defect prevalence in distributed product

FDA recall classification:

Class	Standard	Examples
I	Reasonable probability of serious harm or death	Pathogen contamination, wrong active ingredient, life-threatening device failure
II	Temporary/reversible consequences; remote serious risk	Minor contamination, labeling errors, device defects causing temporary harm
III	Not likely to cause adverse consequences	Minor labeling violations, aesthetic defects

Company proposes classification; FDA assigns final. Complete HHE proportionate to urgency.

4. Recall Strategy

Depth of recall:

Level	Scope	When
Consumer/User	End users; public warnings	Serious hazard + product reached consumers
Retail	Retailers/dispensers only	Hazard manageable at retail; product distinguishable
Wholesale	Wholesale chain only	Product not yet at retail

Public warning required when: Class I + product reached consumers, product not easily distinguished from safe product, or FDA requests it.

Document: Depth justification, public warning plan, timeline, FDA consultation record, adjustment provisions.

5. Notification Protocols

FDA Notification (21 CFR 7.46)

Submit to jurisdictional FDA district office immediately upon initiating recall; no later than 10 working days.

- [ ] Product identity (NDC/device ID, lot numbers)
- [ ] Reason for recall — specific defect
- [ ] HHE and proposed classification
- [ ] Quantity produced and time span
- [ ] Quantity in distribution
- [ ] Distribution pattern (geography, customer types)
- [ ] Proposed strategy (depth, warnings, effectiveness level)

Trade Notifications

Legal + Regulatory must approve before distribution.

- [ ] Prominent "RECALL NOTICE" header
- [ ] Product ID with lot numbers and visual aids
- [ ] Plain-language recall reason
- [ ] Instructions for identifying affected inventory
- [ ] Required actions (quarantine, return, destroy)
- [ ] Lot verification procedure
- [ ] Contact information
- [ ] Request for written confirmation

Public/Consumer Notifications

Coordinate press releases with FDA. Use social media for rapid dissemination. Contact consumers directly when registry data available.

Record all notifications: date/time, recipients, method, copies, responses.

6. Effectiveness Checks

Level	Typical Class	Requirement
A	I	Contact 100% of direct accounts
B	II	Contact representative sample
C	III	Confirm notification receipt

Collect per check: notification receipt confirmation, product identified, quarantine confirmed, quantity reconciliation, sub-distribution info.

Report to FDA: At 2-week, 4-week, and 8-week intervals (or as directed).

Non-responsive escalation: Repeated contact → certified mail with return receipt → personal visit → notify FDA.

7. Product Disposition

Option	When	Requirements
Destruction	Contamination, fundamental defects (default)	Witnessed, certificate (date/method/qty/lots), photo/video for high-value
Reconditioning	Correctable defect; FDA pre-approval	Detailed proposal, QC verification per unit, batch records
Relabeling	Labeling-only; FDA pre-approval	Proposal, per-unit verification, records
Return to mfg	Evaluation/rework	Full chain of custody

Storage: Segregated, restricted access, conspicuously marked, full inventory controls.

Accountability: Periodic reconciliation of distributed vs. returned vs. disposed quantities. Investigate discrepancies. Prevent unauthorized re-entry into distribution.

8. Recall Termination

FDA decides termination, not the company. Never unilaterally declare completion or make public statements suggesting recall has concluded without written FDA agreement.

- [ ] Final effectiveness check results (% accounted for)
- [ ] Quantity reconciliation with explanations for gaps
- [ ] Complete disposition records
- [ ] All recall notifications/communications
- [ ] Outcome summary with lessons learned
- [ ] Formal termination request

9. Post-Recall Review

Monitoring: Handle recalled product surfacing after termination; notify FDA if significant quantities found.

Retention: Complete recall file minimum 2 years beyond termination (longer per litigation holds).

Review checklist:

- [ ] Timeliness of initial HHE
- [ ] Adequacy of recall strategy and mid-course adjustments
- [ ] Effectiveness of notifications
- [ ] Efficiency of recovery and disposition
- [ ] Resource and personnel adequacy
- [ ] Plan gaps identified
- [ ] Root cause / systemic quality issues

Produce written report with CAPA recommendations tracked through QMS.

Pitfalls

• Never self-terminate: Only FDA can authorize recall completion
• Classification is FDA's call: Company proposes; FDA assigns final classification
• Reconditioning/relabeling require pre-approval: Do not proceed without FDA authorization
• Guidance evolves: Flag sections with [VERIFY CURRENT GUIDANCE] where FDA guidance may have changed
• Cross-reference requirements: Medical devices — MDR reporting (21 CFR Part 803) [VERIFY]; Drugs/biologics — field alert reporting (21 CFR 314.81) [VERIFY]
• International distribution: Coordinate with foreign regulatory authorities if distributing outside the US
• Dual audience: Maintain legal precision for counsel while keeping operational sections accessible to non-legal staff